An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases
Lung Cancer, 08/10/2012
Evidence Based Medicine
Sandler A et al. – The authors conclude that clinical trial data indicate that anti–Vascular endothelial growth factor (VEGF) therapy can be considered for non–small cell lung cancer (NSCLC) patients with emerging or pretreated CNS metastases.